The technology provides a method – somatic transgene immunization (STI) – to deliver a nucleic acid molecule such as DNA vaccine into B cells (a cell of the immune system).
STI activates CD4 and CD8 T cells (cells of the immune system), as well as inducing normal T cell memory.
The recently issued claims protect the use of STI for the treatment of any disease indication, including viral and bacterial infections and also tumors, such as cancer of the prostate, colon, lung, breast, melanoma, and others.
Adamis Pharma said that the recently issued claims protect the use of STI to treat viral, bacterial infections (such as e.g. influenza, hepatitis B and C, human papilloma virus, etc.) and also tumors, such as cancer of the prostate, colon, lung, breast, melanoma, and others.
Adamis has also completed Phase 1 study using STI in its TeloB-VAX technology in castrate resistant prostate cancer (CRPC) patients.